Analyzing Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)

LENZ Therapeutics (NASDAQ:LENZ) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Institutional and Insider Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares LENZ Therapeutics and Eloxx Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	6.52	-$82.13 million	($4.09)	-0.97
Eloxx Pharmaceuticals	$6.36 million	9.53	-$5.99 million	($1.54)	-9.74

Eloxx Pharmaceuticals has lower revenue, but higher earnings than LENZ Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its share price is 186,326% less volatile than the S&P 500.

Profitability

This table compares LENZ Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for LENZ Therapeutics and Eloxx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	5	0	2.50
Eloxx Pharmaceuticals	1	0	2	2	3.00

LENZ Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 627.27%. Eloxx Pharmaceuticals has a consensus target price of $38.33, suggesting a potential upside of 155.56%. Given LENZ Therapeutics’ higher probable upside, research analysts plainly believe LENZ Therapeutics is more favorable than Eloxx Pharmaceuticals.

Summary

Eloxx Pharmaceuticals beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.